Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.

In this episode, Urology Times® Assistant Editor Janelle Hart spoke with Amy D. Dobberfuhl, MD, MS, about the presentation, “Feasibility and efficacy of transvaginal onabotulinumtoxinA chemodenervation of the trigone for the third line treatment of refractory overactive bladder,” which was given at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Winter Meeting. Dobberfuhl is a urologist at Stanford Hospitals and Clinics and an assistant professor of urology at the Stanford University School of Medicine in California.

Related Videos
Ricardo M. de Oliveira Soares, MD, answers a question during a Zoom video interview
Patient predictors of postprostatectomy incontinence | Image credit: © jakkapan - stock.adobe.com
Ricardo M. de Oliveira Soares, MD, answers a question during a Zoom video interview
Dr. Woodburn in an interview with Urology Times
Dean Elterman, MD, MSc, FRCSC, in an interview with Urology Times
Anjali Kapur, MD, looks at the camera while answering a question
Anjali Kapur, MD, answers a question about a recent study regarding third-line treatments for OAB
jakkapan - stock.adobe.com
Related Content
© 2023 MJH Life Sciences

All rights reserved.